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AbstrACt
Introduction Robot-assisted laparoscopic prostatectomy 
(RALP) offers potential cure for localised prostate cancer 
but is associated with considerable toxicity. Potency and 
urinary continence are improved when the neurovascular 
bundles (NVBs) are spared during a nerve spare (NS) RALP. 
There is reluctance, however, to perform NS RALP when 
there are concerns that the cancer extends beyond the 
capsule of the prostate into the NVB, as NS RALP in this 
instance increases the risk of a positive surgical margin 
(PSM). The NeuroSAFE technique involves intraoperative 
fresh-frozen section analysis of the posterolateral 
aspect of the prostate margin to assess whether cancer 
extends beyond the capsule. There is evidence from large 
observational studies that functional outcomes can be 
improved and PSM rates reduced when the NeuroSAFE 
technique is used during RALP. To date, however, there has 
been no randomised controlled trial (RCT) to substantiate 
this finding. The NeuroSAFE PROOF feasibility study is 
designed to assess whether it is feasible to randomise 
men to NeuroSAFE RALP versus a control arm of ‘standard 
of practice’ RALP.
Methods NeuroSAFE PROOF feasibility study will be a 
multicentre, single-blinded RCT with patients randomised 
1:1 to either NeuroSAFE RALP (intervention) or standard 
RALP (control). Treatment allocation will occur after trial 
entry and consent. The primary outcome will be assessed 
as the successful accrual of 50 men at three sites over 
15 months. Secondary outcomes will be used to aid 
subsequent power calculations for the definitive full-
scale RCT and will include rates of NS; PSM; biochemical 
recurrence; adjuvant treatments; and patient-reported 
functional outcomes on potency, continence and quality 
of life.
Ethics and dissemination NeuroSAFE PROOF has 
ethical approval (Regional Ethics Committee reference 17/
LO/1978). NeuroSAFE PROOF is supported by National 
Institute for Healthcare Research Research for Patient 
Benefit funding (NIHR reference PB-PG-1216-20013). 
Findings will be made available through peer-reviewed 
publications.
trial registration number NCT03317990.
IntroduCtIon
Nerve sparing (NS) robot-assisted lapa-
roscopic radical prostatectomy (RALP) is 
associated with superior postoperative func-
tional outcomes such as erectile function and 
possibly urinary continence.1 2 While func-
tional results after RP are of importance to 
many men, the primary objective of a cancer 
operation remains complete eradication of 
the tumour.3 Therefore, it is important that 
performing NS RALP does not compromise 
that oncological outcome. Positive surgical 
margins (PSMs) are associated with greater 
risk of biochemical recurrence,4 adjuvant 
therapies (which negate any improved func-
tional outcomes following NS RALP) and 
disease progression. As such, despite the 
improved anatomical understanding and 
strengths and limitations of this study
 ► This is the first feasibility clinical trial to compare 
NeuroSAFE robot-assisted laparoscopic prostatec-
tomy (RALP) to a UK ‘standard of care’ RALP.
 ► Multicentre, randomised controlled trial design.
 ► This is the protocol for a feasibility study, and there-
fore this study is not powered to allow for the analy-
sis of secondary outcomes.
 ► Secondary outcomes include validated patient-re-
ported outcome questionnaires, histological and on-
cological end points, and health economics.
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technological advancement of the robotic platform, NS 
RALP is often eschewed in favour of assuring the safety 
of a negative surgical margin by performing wide exci-
sion around the prostate. Uncertainty in this area is 
compounded by the fact that the accuracy of preoper-
ative imaging techniques and physical examination to 
detect extracapsular extension (ECE) and/or neuro-
vascular cancer involvement are debatable.5 In partic-
ular, pooled data from a recent diagnostic meta-analysis 
found MRI to have a limited sensitivity of 0.57 (95% CI 
0.49 to 0.64) when predicting ECE.6 Therefore, RALP 
can often lead to unwarranted sacrificing of important 
functioning neurovascular bundles (NVBs). When 
deciding whether to perform NS RALP or non-NS RALP, 
surgeons rely on parameters such as preoperative erec-
tile function, D’Amico Risk Classification, radiological 
staging, and location and volume of tumour to cautiously 
assess the safety of an NS approach. These assessments 
may not give a true picture and are prone to subjective 
evaluation. The concept of a frozen section-navigated 
NS during RALP using neurovascular structure adja-
cent frozen section examination of the prostate resec-
tion margin (NeuroSAFE) has been described by the 
Martini-Clinik in Hamburg, Germany.5 7 8 These authors 
and others report benefit in functional outcomes and 
improved oncological safety in their series9 10 though 
other retrospective series are not as clear-cut.11 
The NeuroSAFE technique has not yet been widely 
adopted, as concerns remain that it is time-consuming 
and resource-consuming, has low sensitivity and spec-
ificity and has potentially conflicting oncological 
results.12–15 Neither intraoperative fresh-frozen section 
(FFS) in RALP nor the NeuroSAFE technique have been 
prospectively evaluated by a randomised controlled trial 
(RCT). Moreover, few studies have assessed the impact of 
FFS during RALP on longer term patient outcomes such 
as biochemical recurrence, adjuvant cancer treatments 
(such as radiotherapy and hormones) and comprehen-
sive functional outcomes.
rEsEArCh nEEd
To determine whether the NeuroSAFE technique (FFS of 
the prostate tissue adjacent to the NVBs) during RALP 
is helpful to surgical teams (and therefore patients) who 
are balancing the competing goals of cancer control and 
functional optimisation. An attempt to answer this ques-
tion will require a multidimensional approach focusing 
on preoperative and operative parameters, final histolog-
ical outcomes, adjuvant treatments, quality of life, erec-
tile function, urinary continence and health economics. 
There is recognition that surgical RCTs can be hard to 
recruit to and that patients may not accept their allo-
cated treatment option.16 For this reason, we propose 
to undertake a feasibility study to examine recruitment 
rates, acceptance of allocated treatment and to rehearse 
collection of outcomes.
study AIMs And outCoMEs
The aim is to prospectively recruit for randomisation 
eligible patients to either standard RALP (control arm) 
or NeuroSAFE RALP (intervention arm). This feasibility 
trial has a single-blinded, 1:1 randomised design. This 
article reports the protocol (v.2.0, 6 February 2018) for 
the NeuroSAFE PROOF trial and follows SPIRIT (Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials) reporting guidelines.17
The trial objectives are to assess the feasibility and 
acceptability of:
 ► Recruiting men with localised prostate cancer to an 
RCT of NeuroSAFE RALP versus standard RALP.
 ► Collecting data for outcome measures, including 
patient-reported outcomes.
 ► Estimating treatment effects to inform power calcula-
tions for the definitive full-scale future trial.
 ► The study’s procedures, interventions and follow-up 
regimen among men being treated with RALP for 
localised prostate cancer.
The following criteria will have to be met to proceed to 
a full-scale trial:
 ► Recruitment of 50 men over 15 months from opening. 
Fifty men was decided on to demonstrate that if similar 
recruitment rates were maintained in the full-scale 
NeuroSAFE PROOF study, the trial would be able to 
recruit the several hundreds of men likely necessary 
to appropriately power the said trial over the course 
of approximately 2–3 years.
 ► Recruitment and performance of procedures (both 
intervention and control) as per allocation at three 
prespecified participating sites (UCLH, Bristol and 
Sheffield). At least two treatments (one intervention, 
one control) should be performed at each site.
 ► Methodological or practical issues with the trial 
design should be identified and amended before full-
scale trial.
 ► Good acceptability of the intervention among patients 
and their families, indicated in qualitative feedback 
and public and patient involvement (PPI) events.
 ► Acquisition of comprehensive patient-reported 
outcomes measure including health economics 
questionnaires.
PublIC And PAtIEnt InvolvEMEnt
Patient feedback on the design of the study was obtained 
at two NeuroSAFE PROOF PPI sessions on 12 July 2018 
and 20 September 2018. The second event was attended 
by men participating in NeuroSAFE PROOF. The PPI 
events were supported by Macmillan Cancer (Charity 
no 261017) and Orchid (Charity no 1080540). Partici-
pants, patients and their families were asked specifically 
about the level of blinding, the burden of follow-up 
appointments and priorities in their recovery from 
RALP. Following their feedback, NeuroSAFE PROOF 
now informs men following surgery of their NS status, 
though blinding to allocation status (intervention or 
control) is maintained. Furthermore, men expressed 
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keen preference to know their treatment allocation once 
exiting the 12 months of follow-up period, and this is now 
incorporated into trial design. Patient representatives sit 
on the trial steering committee (TSC) for NeuroSAFE 
PROOF and share oversight of the management of the 
trial. The study is also funded by National Institute for 
Healthcare Research Research for Patient Benefit (NIHR 
RfPB) stream, which has patient members on their deci-
sion panels. On completion of NeuroSAFE PROOF, 
prostate cancer patient groups will be consulted again 
on amendments to the design of the full-scale RCT. The 
results will be published following peer review, and anony-
mised data will be presented at national and international 
conferences.
MEthods And AnAlysIs
trial design
NeuroSAFE PROOF feasibility study is a prospective, 
multicentre, feasibility RCT in patients undergoing 
RALP for localised prostate cancer. Eligible patients will 
be consented and randomised 1:1 to NeuroSAFE RALP 
(intervention) or standard RALP (control) after multidis-
ciplinary team (MDT) review in National Health Service 
(NHS) urological cancer centres. It is not possible to blind 
the surgical team to the treatment received on the day of 
surgery. Researchers for whom knowledge of allocation is 
imperative, that is, those involved in operating on patients 
or coordinating operating lists or pathology teams are not 
blinded to treatment allocation, other members of the 
research team are blinded to treatment allocation. Partic-
ipants are not informed of treatment allocation until 
completing 12 months of follow-up and exiting the study, 
though they are informed of their ultimate nerve spare 
(NS) status (ie, no NS, unilateral NS, bilateral NS). The 
primary outcome is feasibility of recruitment.
Secondary outcomes will include:
 ► Rates of NS performed during RALP.
 ► Rates of PSMs.
 ► Adjuvant therapies and biochemical recurrence.
 ► Patient-reported outcome questionnaires assessing 
potency, urinary continence and quality of life.
 ► Patient-reported healthcare resource diaries.
These outcome measures will allow us to explore the 
feasibility and acceptability of delivering a full-scale multi-
centre RCT. The decision to include 50 feasibility study 
patients in the full-scale NeuroSAFE PROOF trial will 
only be allowed if the feasibility study aligns sufficiently 
closely and will be at the discretion of the independent 
TSC.
trial population
Prior to entry, patients must be accurately staged (eg, 
multiparametric MRI (mpMRI) prostate and cross-sec-
tional imaging to assess for distant metastases (eg, bone 
scan or whole-body MRI)), within 3 months prior to 
randomisation. Eligible patients must have had their case 
discussed at NHS cancer MDT and deemed suitable and 
fit for RALP. Eligible participants will fulfil all the inclu-
sion criteria and none of the exclusion criteria as defined 
below:
Inclusion criteria
1. Men opting to undergo RALP for organ-confined pros-
tate cancer.
2. Potent men (International Index of Erectile Function 
(IIEF) 22–25 not using phosphodiesterase type 5 (PDE-
5) inhibitors or other medications or vacuum pump).
3.  Men who are continent of urine (no self-reported uri-
nary incontinence).
4.  Able to give written informed consent to participate.
Exclusion criteria
1. Unable to undergo RALP.
2. Known overactive bladder.
3. Previous treatment for prostate cancer.
4. Previous/current hormone treatment for prostate can-
cer.
5. NS deemed futile due to locally advanced disease by 
surgeon and radiologist.
An overview of the study schema can be seen in figure 1.
sample size
The primary outcome of NeuroSAFE PROOF is to demon-
strate adequate recruitment to prove feasibility of the 
full-scale definitive NeuroSAFE PROOF RCT. Operative 
data, preliminary functional outcomes data and prelimi-
nary oncological outcomes data from this feasibility data 
will be used to help determine power calculations for the 
full-scale NeuroSAFE PROOF RCT. Previous literature 
suggests that 80% of men undergoing bilateral NS will 
have erections sufficient for penetrative sex, 40% of men 
undergoing unilateral NS and 10% of men undergoing 
no NS.18
recruitment
NeuroSAFE PROOF will recruit patients attending NHS 
cancer centres. All patients who have a diagnosis of pros-
tate cancer and who have been recommended for RALP 
by a specialist NHS regional MDT meeting will be eligible 
to be approached.
Consent
Written informed consent will be obtained from each 
patient prior to study entry and performing baseline trial 
assessments. An ethics committee-approved patient infor-
mation sheet will be provided to facilitate this process. 
Prospective participants will be given at least a week to 
read the patient information sheet prior to being reap-
proached with regards to recruitment. The investigator, 
or their designee, must ensure adequate explanations of 
the trial that participation is voluntary and they can with-
draw at any time. In consenting to the trial, participants 
understand that they are consenting to provide study 
follow-up and data collection. A patient may withdraw 
from the trial at any time without prejudice to his subse-
quent treatment.
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Figure 1 NeuroSAFE PROOF feasibility study schema. EQ-5D-5L, EuroQuol-5 Dimension-5 Level Questionnaire; 
ICIQ, International Consultation on Incontinence Questionnaire; IIEF, International Index of Erectile Function; MDT, 
multidisciplinary team; NS, nerve sparing; PIS, Participant Information Sheet; PSA, Prostate Specific Antigen; RALP, r obot-
assisted laparoscopic prostatectomy.   
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randomisation
Patients will be randomised using an online system 
(https://www. sealedenvelope. com/ trials/) on a 1:1 basis 
to either NeuroSAFE RALP or standard RALP. A comput-
er-generated adaptive minimisation algorithm that 
incorporates a random element will be used to ensure 
treatment groups are balanced (stratified) for centre. 
Treatment allocation will occur after trial entry and 
consent. Participants will not be informed of their treat-
ment allocation until exiting the trial 12 months following 
their surgery. The clinical teams performing and coordi-
nating surgery will not be blinded to treatment allocation 
as this is impractical, and any members of the research 
team not involved in these activities will be blinded.
sEttIng
Participants will be recruited from NHS cancer centres 
undertaking RALP who have the ability to perform the 
additional NeuroSAFE technique. Recruiting sites will be 
invited by the trial management group (TMG). Trial sites 
will have well-developed RALP programmes, routinely 
performing at least 250 cases per year and undergoing 
satisfactory NHS quality assurance and safety visits.
surgeon and unit accreditation
Variations in surgical team performance can produce 
differences in outcomes from RALP.19 As such, to mini-
mise this potential source of confounding, surgeons 
and surgical teams participating in NeuroSAFE PROOF 
feasibility study will require accreditation from the TMG. 
Further, surgeons performing trial treatment need to 
have completed more than 100 cases and have submitted 
these data to the BAUS Oncology database.
robot-assisted laparoscopic prostatectomy
Patients will undergo RALP using the DaVinci surgical 
system as is standard of care in the NHS. All patients will 
undergo a preoperative mpMRI that will be interpreted by 
a consultant genitourinary radiologist with at least 2 years 
experience in reading prostate mpMRIs. The preoper-
ative mpMRI will be interpreted by the radiologist with 
biopsy information and will be used to evaluate presence 
of cancer and likelihood of ECE in zones according to 
the PIRADS anatomic division of the prostate at the base, 
the mid-gland and the apex. In each zone, using a 1–5 
scale (1, definitely absent; 2, probably absent; 3, possibly 
present; 4, probably present; 5 definitely present), they 
will record the likelihood of tumour on each side. Using 
the same 1–5 scale they then indicated the likelihood of 
ECE in each corresponding zone as has been previously 
done by Akin et al.20 Subsequently, the radiologist using 
the mpMRI makes an NS recommendation for each side 
of the prostate for each participant regardless of treat-
ment arm allocation. The radiological NS recommenda-
tion will be recorded:
 ► NS: Yes.
 ► NS: No.
 ► Digital rectal examination dependent.
Control arm: standard rAlP
Standard RALP (control arm) is performed as per NHS 
routine practice. Preoperative parameters used to guide 
surgeon NS decision include mpMRI review with geni-
tourinary radiologist recommendation with regards NS, 
prostate biopsy histology and digital rectal examination 
under general anaesthesia. Individual surgeons are asked 
after RALP to grade the quality of NS performed on each 
side numerically as seen below as previously described21:
 ► Grade 4: No NS. Wide excision of lateral pelvic fascia 
(LPF) and Denonvilliers’ fascia.
 ► Grade 3: Limited NS or partial/incremental NS. Inci-
sion through outer compartment of LPF.
 ► Grade 2: Interfascial NS. LPF is taken just outside the 
layer of the veins of the prostate capsule. Still largely 
preserving the large neural trunks (also known as the 
NVBs).
 ► Grade 1: Intrafascial NS. LPF is taken just outside the 
prostate capsule. Represents greatest possible NS.
Detailed times of starting the RALP and finishing the 
RALP are recorded on the day of surgery to calculate the 
length of each case.
Intervention arm: neurosAFE rAlP
NeuroSAFE RALP (intervention arm) will be performed 
in accordance with previously described methods, initially 
developed at the Martini Clinik, Hamburg, Germany.5 8 22 
The additional steps outlined include NS technique and 
apical dissection, specimen removal, intraoperative 
frozen section protocol, simultaneous urethravesical 
anastomosis (with/without pelvic lymphadenectomy 
where performed), pathological processing of specimen, 
pathology-reporting protocol and secondary excision of 
the NVB (where appropriate). Detailed results of the 
FFS examination will be collected and included in the 
results, including number of sections positive, length of 
positive margin, identity and grade of pathologist. When 
the frozen section examination demonstrates cancer at 
the margin of the prostate as per pathology-reporting 
protocol, secondary excision of the NVB is described by 
the surgeon in one of three ways: (1) No tissue resected, 
(2) Local excision of Denonvilliers’/periprostatic fascia 
or (3) Entire bundle resected. Secondarily resected tissue 
(after FFS pathology phone call, when performed) is sent 
for routine paraffin-embedded histological analysis and 
is not analysed as part of the intraoperative FFS. Detailed 
times of the beginning of the RALP, the removal of the 
prostate for specimen painting, arrival of specimen 
in laboratory, communication of details of FFS to the 
surgical team and finishing the RALP are recorded on 
the day of surgery.
Participating sites all visited the central site (UCLH) 
prior to their Site Initiation Visits to receive teaching 
and standardisation in the surgical and histopatholog-
ical aspects of NeuroSAFE RALP (intervention arm). 
Subsequently, researchers from the central site (GS and 
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AH) reciprocated the visit for the first NeuroSAFE RALP 
performed by each site to ensure fidelity to technique 
protocol.
data collection
Post-treatment trial assessments will be conducted at 
follow-up appointments. All patients will have follow-up 
appointments at 6 weeks following surgery, 3 months, 
6 months and finally 12 months following their treatment. 
Table of assessments is demonstrated below (table 1).
time points
1. Baseline/preoperative: at the time of consent, trial en-
try and randomisation to treatment allocation.
2. Visit 1: operative parameters recorded and any imme-
diate postoperative complications/adverse events.
3. Outpatient follow-up: visits 2, 3, 4 and 5 will record 
patient-reported outcome measures and healthcare 
resource diaries. Adjuvant treatments and oncologi-
cal outcomes will be recorded prospectively alongside 
functional assessments.
4. On visits 3, 4 and 5, a serum PSA will be taken in ad-
dition to functional questionnaires and adjuvant treat-
ment outcomes.
secondary end point measures
Secondary end point measures include:
1. IIEF-15 (baseline, 6 weeks, 3 months, 6 months and 
12 months): a self-completion tool for men focusing 
on erectile function and sex life. Measured domains in-
clude erectile function, orgasmic function, sexual de-
sire, intercourse satisfaction and overall satisfaction.23
2. Rand 36-Item Health Survey (baseline, 6 weeks, 
3 months, 6 months and 12 months): a self-comple-
tion questionnaire that laps eight concepts: physi-
cal functioning, bodily pain, role limitations due to 
health problems, role limitations due to personal 
or emotional problems, emotional well-being, social 
functioning, energy/fatigue and general health per-
ceptions.24
3. International Consultation on Incontinence Question-
naire (ICIQ) (baseline, 6 weeks, 3 months, 6 months 
and 12 months): a self-completion tool for patients to 
subjectively measure frequency and severity of urinary 
loss, and impact on quality of life for those with urinary 
incontinence.25
4. EQ-5D-5L (baseline, 6 weeks, 3 months, 6 months and 
12 months): a self-completion tool for patients that is 
applicable to a wide range of health conditions and 
treatments. Measured domains include mobility, self-
care, usual activities, pain and anxiety or depression.26
5. Health resource diaries (6 weeks, 3 months, 6 months, 
6-month visit diary will be returned at the 12-month 
visit). This will allow the collection of resource use data 
from point of operation until trial exit at 12 months. 
These diaries are non-validated.
6. Postoperative: adverse events and complications will 
be recorded. Clavien–Dindo classification of surgical 
complications will be used to assess for any surgical 
complications as per normal hospital practice.
7. Histology: following RALP, the following details will 
be recorded as per standard histological analysis 
of prostatectomy mount: histological type, Gleason 
grade, Gleason group, tumour volume, extraprostatic 
extension, seminal vesicle involvement, lymphovascu-
lar invasion, description of margin involvement (in-
cluding apical, basal, circumferential), tumour stage, 
nodes, PSMs.
8. Oncological outcomes (3 months, 6 months and 
12 months): the curative outcomes from RALP will be 
examined to determine local and distant recurrence, 
metastases, PSA and biochemical recurrence, need for 
adjuvant therapies and survival (overall and cancer 
specific).
Table 1 Table of assessments
Baseline/
recruitment
Visit 1
treatment
Visit 2
(6 weeks 
post-RALP)
Visit 3
(3 months)
Visit 4
(6 months)
Visit 5
(12 months)
Informed consent x
Randomisation x
PSA x x x x
Standard RALP or NeuroSAFE RALP x
Adverse events x x
EQ-5D-5L, ICIQ, Rand 36 x x x x x
IIEF x x x x x
Adjuvant therapies x x x x
Health resource diary x x x x
ICIQ, International Consultation on Incontinence Questionnaire; IIEF, International Index of Erectile Function; RALP, robotassisted laparoscopic 
prostatectomy. ICIQ, International Consultation on Incontinence Questionnaire; IIEF, International Index of Erectile Function; RALP, robot-
assisted laparoscopic prostatectomy.
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stAtIstICAl AnAlysIs
As NeuroSAFE PROOF is a feasibility trial, there is no 
intention to undertake detailed statistical analysis. Prelim-
inary analysis will be performed after five cases have 
reached ‘visit 3’ to rehearse data extraction, completeness 
of follow-up, fidelity of data and by proxy acceptability 
of follow-up measures. Further preliminary data anal-
ysis, maintaining blinding, of the secondary outcomes 
‘margin status’ and ‘RALP NS status’ will be performed by 
the data monitoring committee (DMC) after 40 surgeries 
have been performed to evaluate and help revise power 
estimations for the full-scale RCT. Potential bias due to 
missing data will be investigated by comparing descrip-
tively the baseline characteristics of the trial participants 
with complete outcome measurements to those who have 
missing outcome measurements. Men will be offered the 
option of telephone follow-up and/or be sent question-
naires by post if they are unable to attend clinic appoint-
ments for follow-up. Additionally, patients wishing to 
withdraw from the trial will be counselled regarding end 
of active participation, as this will allow the trial team to 
continue to use their outcome data for an intention-to-
treat analysis. Records will be kept of all participants allo-
cated to a treatment arm who do not undergo allocated 
treatment with explanatory notes. These instances will be 
highlighted to the Surgical & Interventional Trial Unit at 
University College London (study sponsor) (SITU) and 
the TSC for judgement on whether inclusion in outcomes 
is appropriate.
sAFEty
The number of adverse events related to serious adverse 
events (SAEs) will be summarised descriptively by arm, by 
grade and body system. RALP is a major surgery that has 
a number of recognised complications and a very low risk 
of death (less than 1 in 100). Operative/postoperative 
RALP complications will be graded using the Clavien–
Dindo classification. The central trial management team 
will ask sites to submit complication data blinded by arm 
of treatment. This will be assigned Clavien–Dindo classifi-
cation centrally.27 All SAEs will be recorded in the medical 
records, the case report form, the sponsor’s adverse event 
log and an SAE form. The site principal investigator (PI) 
or designated individual will complete an SAE form, and 
the form will be sent to SITU within 5 working days of 
becoming aware of the event. The study chief investigator 
or site PI will respond to any SAE queries raised by the 
sponsor as soon as possible. Where the event is unex-
pected and thought to be related to the procedure, this 
must be reported by the PI to SITU, who will then inform 
the Health Research Authority within 15 days.
dAtA MonItorIng
This trial will use an electronic case report form (eCRF), 
and trial data will be entered into an approved, protected 
database (https:// neurosafe. slms. ucl. ac. uk). Access to 
the eCRF system will only be provided to staff with the 
appropriate authority. Participants will be given a unique 
number and subject identifier. Data will be entered 
under this identification number onto the central data-
base stored on the servers. The database will be password 
protected and only accessible to members of the Neuro-
SAFE study team as well as external regulators if requested. 
The servers are protected by firewalls and are patched 
and maintained according to best practice. The physical 
location of the servers is protected by CCTV and security 
door access. The database software provides a number of 
features to help maintain data quality, including: main-
taining an audit trail, allowing custom validations on 
all data, allowing users to raise data query requests and 
search facilities to identify validation failure/missing 
data. After completion of the study, the database will be 
retained on the servers of University College London 
for ongoing analysis of secondary outcomes. The iden-
tification, screening and enrolment logs, linking partic-
ipant identifiable data to the pseudoanonymised subject 
numbers will be held in written form in a locked filing 
cabinet. After completion of the study, sites will store 
screening and enrolment logs securely for 10 years.
trIAl FundIng, orgAnIsAtIon And AdMInIstrAtIon
The trial was developed by the NeuroSAFE PROOF TMG 
and has been funded by University College London 
Hospitals NHS Foundation Trust (UCLH), The Rosetrees 
Foundation and the NIHR Research for Patient Benefit 
(RfPB) stream (reference: PB-PG-1216-200113). Applied 
Medical are contributing disposable laparoscopic trocar 
ports suitable for use in NeuroSAFE RALP (intervention 
arm), but the company has had no role in trial design 
and will have no role in trial implementation, analysis, 
interpretation or writing any reports. The trial is spon-
sored by University College London and has registered 
sponsor reference number 17/0443 and  ClinicalTrials. 
gov (NCT03317990) on 23 October 2017 with an amend-
ment made on 1 June 2018. All members of the trial 
are Good Clinical Practice trained. A DMC will monitor 
patient safety and the rate of recruitment of subjects in 
the study. They will meet at least once a year while the 
trial is ongoing for routine review of safety data and trial 
progression. They have power to call additional meet-
ings and review data at any point in the trial should they 
wish to do so. The DMC may report their findings to the 
TSC. The TSC is an independent committee consisting 
of relevant, experienced clinicians and researchers. The 
TSC will ensure the study is conforming to governance 
requirements as set out by the trial sponsor. The TSC will 
meet at least once a year. The sponsor may also arrange 
an independent trial monitor to review the study data.
EthICs And dIssEMInAtIon
Ethical approval for NeuroSAFE PROOF was granted 
on 6 February 2018 (regional ethics committee (REC) 
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reference 17/LO/1978). Here, we report version 2.0 of 
the protocol. The sponsors, health resources approval 
(HRA) body and REC will approve any future amend-
ments as appropriate. Similarly, all participating sites have 
(or will have) gained local REC prior to receiving a site 
initiation visit and being given the permission to open 
recruitment.
Non-blinded results of the study will be published in 
peer-reviewed publications and will be presented at rele-
vant national and international conferences. The TMG 
will not present the arms in comparison to one another to 
avoid loss of equipoise and introduction of bias into the 
full-scale RCT. The TMG will work with a patient panel 
to develop lay reports to disseminate research findings 
to patient groups and the clinical teams at participating 
sites.
dIsCussIon
Intraoperative FFS analysis of the NVB adjacent prostate 
margin during RALP to guide NS is now an established 
technique in a number of centres. Published large series 
from these centres demonstrate improvements on their 
outcomes, both functional and oncological. In spite of 
the possible benefit to men with localised prostate cancer 
undergoing surgery, the NeuroSAFE technique during 
RALP has not been widely introduced in the UK. The lack 
of level 1 evidence to support NeuroSAFE RALP is a valid 
reason for this.
The NeuroSAFE PROOF RCT feasibility study will 
be the first trial to assess the feasibility of conducting a 
randomised trial to evaluate intraoperative frozen section 
evaluation of the prostate margin during RALP anywhere 
in the world. The results of this feasibility trial will be used 
to prepare the full-scale NeuroSAFE PROOF RCT.
trial status
NeuroSAFE PROOF RCT feasibility study opened to 
recruitment in April 2018 using protocol version 2.0 
(6 February 2018) and is due to close to recruitment 
in January 2020 or after the 50th patient is consented 
and randomised. NeuroSAFE PROOF RCT feasibility 
study will therefore close in January 2021 or when the 
last participant to undergo treatment completes the 
12-month follow-up as per protocol. Amendments were 
reviewed and approved by the sponsor and the REC. 
Protocol amendments are disseminated to relevant 
parties by SITU.
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